Company Filing History:
Years Active: 2019-2021
Title: Andrea Wagenfeld: Innovator in Gynecological and Metabolic Therapies
Introduction
Andrea Wagenfeld is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of selective progesterone receptor modulators and their prodrugs. With a total of two patents to her name, Wagenfeld's work is paving the way for advancements in therapeutic applications.
Latest Patents
Wagenfeld's latest patents include innovative compounds that address various medical conditions. One of her notable inventions is the prodrug of the selective progesterone receptor modulator (SPRM), specifically the compound (11.beta.,17.beta.)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one. This invention focuses on the therapeutic applications of SPRMs in a prodrug form. Another significant patent involves the compound [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones, which covers a range of pharmaceutical compositions aimed at treating gynecological, hyperproliferative, metabolic, and inflammatory disorders.
Career Highlights
Andrea Wagenfeld is currently employed at Bayer Pharma Aktiengesellschaft, where she continues to innovate in the pharmaceutical sector. Her work is characterized by a strong focus on developing compounds that can significantly improve patient outcomes in various medical fields.
Collaborations
Wagenfeld collaborates with esteemed colleagues, including Antje Rottmann and Horst Irlbacher. These partnerships enhance her research and development efforts, contributing to the advancement of her innovative projects.
Conclusion
Andrea Wagenfeld is a key figure in the pharmaceutical industry, with her inventions poised to make a lasting impact on the treatment of various disorders. Her dedication to innovation and collaboration underscores her role as a leading inventor in her field.